RRML - Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR

Main page
News
RJLabM Credits
Archive
- Current issue
- Ahead of print
- List of published issues
- 2024
  - Nr.4/2024
  - Nr.3/2024
  - Nr.2/2024
  - Nr.1/2024
  - Supplement 1/2024
- 2023
  - Nr.4/2023
  - Nr.3/2023
  - Nr.2/2023
  - Nr.1/2023
  - Supplement 1/2023
- 2022
  - Nr.4/2022
  - Nr.3/2022
  - Nr.2/2022
  - Nr.1/2022
  - Supplement 1/2022
- 2021
  - Nr.4/2021
  - Nr.3/2021
  - Nr.2/2021
  - Nr.1/2021
- 2020
  - Nr.4/2020
  - Nr.3/2020
  - Nr.2/2020
  - Nr.1/2020
  - Supplement 1/2020
- 2019
  - Nr.4/2019
  - Nr.3/2019
  - Nr.2/2019
  - Nr.1/2019
  - Supplement 1/2019
- 2018
  - Nr.4/2018
  - Nr.3/2018
  - Nr.2/2018
  - Nr.1/2018
  - Supplement 1/2018
  - Supplement 2/2018
  - Supplement 3/2018
- 2017
  - Nr.4/2017
  - Nr.3/2017
  - Nr.2/2017
  - Nr.1/2017
  - Supplement 1/2017
- 2016
  - Nr.4/2016
  - Nr.3/2016
  - Nr.2/2016
  - Nr.1/2016
  - Supplement 1/2016
- 2015
  - Nr.4/2015
  - Nr.3/2015
  - Nr.2/2015
  - Nr.1/2015
  - Supplement 1/2015
- 2014
  - Nr.4/2014
  - Nr.3/2014
  - Nr.2/2014
  - Nr.1/2014
  - Supplement 1/2014
- 2013
  - Nr.4/2013
  - Nr.3/2013
  - Nr.2/2013
  - Nr.1/2013
  - Supplement 1/2013
- 2012
  - Nr.4/2012
  - Nr.3/2012
  - Nr.2/2012
  - Nr.1/2012
  - Supplement 1/2012
- 2011
  - Nr.4/2011
  - Nr.3/2011
  - Nr.2/2011
  - Nr.1/2011
  - Supplement 1/2011
- 2010
  - Nr.4/2010
  - Nr.3/2010
  - Nr.2/2010
  - Nr.1/2010
  - Supplement 1/2010
- 2009
  - Nr.4/2009
  - Nr.3/2009
  - Nr.2/2009
  - Nr.1/2009
  - Supplement 1/2009
- 2008
  - Nr.4/2008
  - Nr.3/2008
  - Nr.2/2008
  - Nr.1/2008
  - Supplement 1/2008
- 2007
  - Nr.4/2007
  - Nr.3/2007
  - Nr.2/2007
  - Nr.1/2007
- 2006
  - Nr.4/2006
  - Nr.3/2006
  - Nr.2/2006
  - Nr.1/2006
- 2005
  - Nr.1/2005
Instructions for authors
Online applications
- Send an article
- Online payments
Editorial
About us
Links

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Top 10 downloaded articles - January 2025 -

Investigation of cytokine chan...	10
Romanian Review of Laboratory ...	9
Biomarkers of acute kidney inj...	8
Expressions of vascular endoth...	7
Recomandările naționale ale ...	7
Monocyte to high-density lipop...	6
Effect of Systemic Inflammator...	6
Translation of the MARS questi...	6
Correlation between fecal biom...	6
Study of the antimicrobial act...	5

Concept, Design & Programming
Dr. Adrian Man

Nr. 13(4)/2008

Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR

Delia Dima, Adrian P Trifa, Andrei Cucuianu, Radu A Popp, Mariana Paţiu, Ljubomir Petrov

Abstract:

The introduction of imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia. Even though experience with imatinib mesylate is limited, clinical resistance has already been observed. In order to overcome imatinib resistance, more potent tyrosine kinase inhibitors such as nilotinib and dasatinib have been developed, with demonstrable activity against most BCR-ABL domain mutations with the notable exception of T315I mutation. Moreover, with the increased use of newer tyrosine kinase inhibitors it has been suggested that the spectrum of mutations may change, possibly selecting the pan-resistant T315I. That is why mutational analysis should be done on a regular basis or at any time the clinical and hematological aspects change, in order to give the patient the best therapy available.

Keywords: imatinib,tyrosine kinase,mutation,T315I

Download full text PDF
(66 KB)

Dima D, Trifa AP, Cucuianu A, Popp RA, Paţiu M, Petrov L. Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR. Rev Romana Med Lab. 2008;13(4):17-20